Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

PROTAGONIST THERAPEUTICS, INC : Submission of Matters to a Vote of Security Holders (form 8-K)

05/28/2021 | 05:31pm EST

Item 5.07. Submission of Matters to a Vote of Security Holders

At the Protagonist Therapeutics, Inc. (the "Company") 2021 Annual Meeting of Stockholders (the "Annual Meeting") held on May 27, 2021, the stockholders voted on the two proposals listed below. The proposals are described in detail in the Company's definitive proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission on April 14, 2021. The results of the matters voted upon at the meeting were:

Proposal 1 - To elect the three Class II directors named below to serve until the 2024 Annual Meeting of Stockholders. Each of the three named nominees was so elected, with the votes thereon at the Annual Meeting as follows:



                                                   Final Voting Results
Nominees                                    For       Withheld    Broker Non-Votes
Sarah A. O'Dowd                          38,323,022    306,101       2,984,809
William D. Waddill                       34,282,286   4,346,837      2,984,809

Lewis T. "Rusty" Williams, M.D., Ph.D. 34,296,520 4,332,603 2,984,809

Proposal 2 - To ratify the selection by the Audit Committee of the Board of Directors of the Company of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021. This proposal was approved by the requisite vote, with the votes thereon at the Annual Meeting as follows:



              Final Voting Results
   For       Against   Abstain   Broker Non-Votes
41,608,911    4,897      124            -



No other matters were submitted for stockholder action.

© Edgar Online, source Glimpses

All news about PROTAGONIST THERAPEUTICS, INC.
01/04/C O R R E C T I O N -- Protagonist Therapeutics, Inc./
PR
2021INSIDER SELL : Protagonist Therapeutics
MT
2021Protagonist Therapeutics Presents Updated Phase 2 Rusfertide Data
CI
2021Protagonist Therapeutics to Present at the JMP Securities Hematology and Oncology Summi..
PR
2021Protagonist Therapeutics Picks PN-235 for Mid-Stage Trials in Multiple Indications
MT
2021Protagonist Therapeutics Announces the Selection of Oral Peptide PN-235 into Phase 2 Cl..
PR
2021Protagonist Therapeutics Announces Selection of Oral Peptide PN-235 into Phase 2 Clinic..
CI
2021Protagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use ..
AQ
2021Protagonist Therapeutics Announces 'Positive Data' for Rusfertide as Possible Hereditar..
MT
2021JMP Securities Adjusts Price Target on Protagonist Therapeutics to $70 From $60, Keeps ..
MT
More news
Analyst Recommendations on PROTAGONIST THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 23,8 M - -
Net income 2021 -127 M - -
Net cash 2021 248 M - -
P/E ratio 2021 -10,7x
Yield 2021 -
Capitalization 1 383 M 1 383 M -
EV / Sales 2021 47,6x
EV / Sales 2022 47,5x
Nbr of Employees 116
Free-Float 98,9%
Chart PROTAGONIST THERAPEUTICS, INC.
Duration : Period :
Protagonist Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROTAGONIST THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 28,97 $
Average target price 59,00 $
Spread / Average Target 104%
EPS Revisions
Managers and Directors
Dinesh V. Patel President, Chief Executive Officer & Director
Donald A. Kalkofen Chief Financial Officer
Harold E. Selick Chairman
Mark L. Smythe Vice President-Technology
David Y. Liu Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
PROTAGONIST THERAPEUTICS, INC.-15.29%1 383
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
IQVIA HOLDINGS INC.-14.60%46 031
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508